I. MODIFIED AGREEMENTS | |||
| |||
Biotech Co.* |
Pharma Co. |
Change from original agreement | Terms/Details (Date) |
| | |||
| |||
BioXell SpA* |
F. Hoffmann-La Roche Ltd. (Switzerland) |
BioXell gained additional rights to BXL 628 to include all nontopical and nonderma-tological applications |
BioXell already held rights in several indications; terms were not disclosed (6/28) |
| |||
Chemical Diversity Labs Inc.* |
Gedeon Richter Ltd. (Hungary) |
Extended agreement under which Chemical Diversity provides discovery chemistry libraries and medicinal chemistry services |
The deal was extended through 2006; terms were not disclosed (8/9) |
| |||
Crucell NV (the Netherlands; CRXL) |
GlaxoSmithKline plc (UK) |
GSK renewed its PER.C6 license for R&D of viral- vectored products |
Crucell gets undisclosed up-front and annual payments; GSK has an option to get a commercial license (7/6) |
| |||
Europroteome |
Abbott Laboratories |
They extended deal for the discovery and development of breast cancer diagnostics |
The February 2004 deal was extended after reaching an undisclosed project milestone (7/15) |
| |||
Genedata AG* (Switzerland) |
Altana AG |
Expanded deal under which Genedata will provide enterprise-wide computing infrastructure |
The original license five years ago covered Genedata's scientific computing platform; Altana will use the technology in target discovery and lead identification (6/29) |
| |||
Immunomedics |
Schering AG (Germany) |
Settled issues related to in vitro products covered under Immunomedics' CEA patents |
Schering unit CIS Bio International will pay Immunomedics an undisclosed sum for past sales of the products (7/7) |
| |||
Interleukin |
Access Business Group (subsidiary of Alticor Inc.) |
Expanded deal to include development of a test to identify genetic variations that affect weight gain |
IGI can get $1.9M over a 12-month proof- of-concept period; IGI also will help in developing nutritional products to help manage weight (7/1) |
| |||
Karo Bio AB (Sweden; SSE:KARO) |
Wyeth |
Extended for one year deal to discover drugs targeting the liver X receptor |
The three-year deal was extended to Aug. 31, 2005, and is focused primarily on atherosclerosis; terms were not disclosed (6/18) |
| |||
Medivir AB |
Novartis AG (Switzerland) |
They resolved issues related to partly overlapping patents in the U.S. on Medivir's ME-609 product |
Medivir gets exclusive rights to topical combination products containing the antiviral acyclovir; Novartis gets a non-exclusive license to certain antiviral combination products, while Medivir retains the exclusive rights to its formulation patent relating to combinations containing penciclovir (8/13) |
| |||
Neuro3d SA* |
Johnson & Johnson Pharmaceutical Research & Development |
Extended collaboration after J&J identified a compound for further characterization from Neuro3d's libraries |
Details were not disclosed (7/21) |
| |||
Prana Biotechnology Ltd. (Australia; PRAN) |
P.N. Gerolymatos SA (Greece) to the Alzheimer's disease |
They, along with Massachusetts General Hospital, resolved all pending litigation related and will pay Prana a percentage of income; drug lioquinol |
Prana will hold rights in the U.S. and Japan, and pay royalties on those sales; Gerolymatos holds rights in Europe and elsewhere, PRAN) Prana will allot 1.35M shares that will beheld in escrow for 12 months (8/9) |
| |||
Sepracor Inc. |
Paul Royalty Fund II LP |
Paul Royalty acquired royalty rights to Sepracor's Estorra from Aventis SA |
Paul Royalty will pay Aventis up to $115M in fixed and milestone payments following product launch (8/9) |
| |||
Symyx Technologies Inc. (SMMX) |
Dow Chemical Co. |
Extended collaboration to discover catalysts to produce polyolefins, which are polymers used in various products |
The 1999 deal was extended through 2004, giving them time to define future business arrangements (6/30) |
| |||
II. TERMINATED AGREEMENTS | |||
| |||
Alliance Pharmaceutical Inc. (OTC BB:ALLP) |
Nycomed Group (Denmark) |
Terminated deal signed in April under which Nycomed would commercialize Oxygent in Europe |
The move was made after an opinion by European regulators suggesting more clinical study would be needed on the blood substitute than originally anticipated (7/6) |
| |||
AVI BioPharma Inc. (AVII) |
Medtronic Inc. |
Ended deal on the delivery of AVI's antisense therapy Resten-NG, via devices, in cardiovascular diseases |
The deal was signed in 2001 and modified in 2003; AVI regains full exclusive rights to Resten-NG in all cardiovascular applications, including device delivery (6/30) |
| |||
Elite Pharmaceuticals Inc. (AMEX:ELI) |
Purdue Pharma LP |
Purdue allowed to lapse its exclusive option to apply abuse-resistant technology to oxycodone |
Elite intends to recommence negotiations on licenses to the technology with other companies (8/4) |
| |||
Generex Biotechnology |
Eli Lilly and Co. |
Ended deal to develop and commercialize buccal delivery of insulin |
Generex regains full rights to the technology, which includes its Oralin product; Lilly will continue supplying insulin (6/23) |
| |||
Geron |
Kyowa Hakko Kogyo Co. Ltd. (Japan) |
Kyowa Hakko returned Asian rights for Geron's telomerase inhibitors |
They said Kyowa Hakko is refocusing its oncology development programs (6/30) |
| |||
Illumina |
Applera Corp. and its Applied Biosystems Group |
Companies settled litigation related to a 1999 development agreement; the settlement ended the agreement |
They agreed to royalty-free cross-licenses and an $8.5M payment from Illumina to Applera, part of $10M it received earlier in the deal in R&D funding (8/19) |
| |||
Inex |
GlaxoSmithKline plc (UK) |
GSK is terminating their deal to develop liposomal topotecan (INX-0076; Hycamtin) effective Sept. 1, 2004 |
The deal to apply Inex liposomal technology to the GSK compound began in 2001; GSK ran into manufacturing difficulties (8/4) |
| |||
Novavax Inc. (NVAX) |
King Pharmacueticals Inc. |
Novavax regained full rights to Estrasorb, as well as all rights to other women's health products Novavax may develop using micellar nanoparticle technology |
They ended a co-promotion deal on the product; Novavax will pay King $22M in cash and issue 3.78M shares, giving King about 10.4% of Novavax; Novavax will reacquire convertible notes held by King and acquire part of King's women's health sales force; King will pay Novavax $8M to support marketing efforts (7/19) |
| |||
Notes: | |||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange. | |||
